脑室内药物治疗联合或不联合脑室分流术治疗不同颅内压的软脑膜转移:单中心大规模回顾性研究
本研究回顾性分析125例软脑膜转移患者,均行Ommaya储液囊置入和/或脑室分流术并术后接受脑室内药物治疗,评估症状缓解、生存及预后因素。结果显示,113例颅内高压患者行脑室分流术后症状显著缓解;112例(89.6%)规律接受药物治疗者中位生存期9.0个月,较文献中未用脑室内药物治疗的研究延长2-4个月。Cox多因素分析显示术后脑室内药物治疗及治疗次数独立影响疗效。
要点
- 脑室分流术可显著缓解软脑膜转移合并颅内高压患者的症状,并避免严重颅内高压患者猝死。
- 脑室内药物治疗可有效控制软脑膜转移,显著延长生存期并提高生活质量。
- 术后脑室内药物治疗及治疗次数是软脑膜转移治疗疗效的独立影响因素。
核心结论
- 对于软脑膜转移,脑室分流术不仅显著缓解颅内高压所致症状,还能避免严重颅内高压患者猝死,但单纯脑室分流术不改善总生存。
- 脑室内药物治疗可有效控制软脑膜转移,显著延长生存期并提高生活质量。
研究设计与样本
- 单中心大规模回顾性研究,纳入2021年4月至2022年12月在本院治疗的125例软脑膜转移患者,均行Ommaya储液囊置入和/或脑室分流术,术后接受脑室内药物治疗。
- 评估症状缓解程度、生存情况及影响预后的因素,采用Kaplan-Meier法计算3个月、6个月、1年生存率及中位生存期,采用log-rank检验、单因素方差分析和Cox比例风险模型进行生存及预后分析。
主要发现
- 113例合并颅内高压的软脑膜转移患者行脑室分流术后症状显著缓解。
- 112例(89.6%)规律接受药物治疗的患者中位生存期为9.0个月,较文献中未涉及脑室内药物治疗的其他研究延长2-4个月。
- Cox多因素分析显示,术后脑室内药物治疗及脑室内药物治疗次数独立影响软脑膜转移的治疗疗效。
临床怎么用
- 对于软脑膜转移合并颅内高压的患者,可行脑室分流术以显著缓解症状并避免猝死。
- 脑室内药物治疗可有效控制软脑膜转移,显著延长生存期并提高生活质量。
- 术后脑室内药物治疗及治疗次数是影响疗效的独立因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and prognosis of intraventricular medication (IVM) administered via the reservoir of Ommaya or ventricular shunt (VS) system to control leptomeningeal metastases, with or without VS based on intracranial pressure, in combination with postoperative systemic therapy. METHODS: Between April 2021 and December 2022, 125 patients with leptomeningeal metastases were managed in our department who underwent Ommaya reservoir placement and/or VS and subsequently received IVM postoperatively. The extent of symptom amelioration and survival, as well as the determinants influencing prognosis, were evaluated. The 3-, 6-month, and 1-year survival rates and mOS of the patients were calculated by the Kaplan‒Meier method, and survival and prognostic analyses were performed using the log-rank test, one-way analysis of variance, and the Cox proportional hazards model. RESULTS: Symptoms were significantly alleviated among the 113 leptomeningeal metastases with intracranial hypertension who underwent VS placement. The median survival time of 112(89.6%)cases who received medication regularly was 9.0 months, and significantly prolonged by 2-4 months compared with that of other studies not involving IVM in the literature. Cox multifactorial analysis revealed that postoperative administration of IVM and the number of IVM times independently influenced the efficacy of leptomeningeal metastases treatment. CONCLUSIONS: For leptomeningeal metastases, VS not only significantly alleviates symptoms caused by intracranial hypertension but also avoids sudden death for those with severe intracranial hypertension. However, VS placement only does not improve overall survival. IVMs controls effectively leptomeningeal metastases, significantly prolongs survival, enhances quality of life.
引用
- Zhao S, Sun P, Zhang X, et al. Intraventricular Medication with or without Ventricular Shunt for Leptomeningeal Metastases with Different Intracranial Pressure: A Single-Center, Large-Scale Retrospective Study. World Neurosurg. 2025. PMID: 39662621. doi:10.1016/j.wneu.2024.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。